NCT01348087 - Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X Syndrome | Biotech Hunter

Enrollment

148

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions

Fragile X Syndrome

Interventions

DRUG

AFQ056

The investigational drug, AFQ056, will be provided as hard gelatin capsules. Two different oral dosage strengths, identical in appearance, will be used.

Trial Locations (28)

1011

Novartis Investigative Site, Lausanne

2112

Novartis Investigative Site, Ryde

2298

Novartis Investigative Site, Waratah

2600

Novartis Investigative Site, Glostrup Municipality

3161

Novartis Investigative Site, Caulfield

8091

Novartis Investigative Site, Zurich

10314

Novartis Investigative Site, Staten Island

12203

Novartis Investigative Site, Berlin

16147

Novartis Investigative Site, Genova

19063

Novartis Investigative Site, Media

29010

Novartis Investigative Site, Málaga

30033

Novartis Investigative Site, Decatur

37212

Novartis Investigative Site, Nashville

46202

Novartis Investigative Site, Indianapolis

55131

Novartis Investigative Site, Mainz

60612

Novartis Investigative Site, Chicago

69677

Novartis Investigative Site, Bron

72076

Novartis Investigative Site, Tübingen

75013

Novartis Investigative Site, Paris

85006

Novartis Investigative Site, Phoenix

95817

Novartis Investigative Site, Sacramento

97070

Novartis Investigative Site, Würzburg

02115

Novartis Investigative Site, Boston

68198-5575

Novartis Investigative Site, Omaha

L6Y 1M5

Novartis Investigative Site, Brampton

J1H 5N4

Novartis Investigative Site, Sherbrooke

08190

Novartis Investigative Site, Sant Cugat del Vallès

EH10 5HF

Novartis Investigative Site, Edinburgh